参考文献/References:
[1]Namikawa T, Munekage E, Fukudome I, et al. Clinicopathological characteristics and therapeutic outcomes of synchronous gastric adenocarcinoma and gastric lymphoma. Anticancer Res,2014,34(9):5067-5074.
[2]Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN guidelines insights: Bcell lymphomas, Version 3.2019. J Natl Compr Canc Netw,2019,17(6):650-661.
[3]Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and nonHodgkin lymphoma: the Lugano classification. J Clin Oncol,2014, 32(27):3059-3068.
[4]Hatta W, Gotoda T, Koike T, et al. History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer. Dig Endosc,2020,32(2):180-190.
[5]Ishikawa E, Nakamura M, Shimada K, et al. Prognostic impact of PDL1 expression in primary gastric and intestinal diffuse large Bcell lymphoma. J Gastroenterol,2020,55(1):39-50.
[6]秦燕,何小慧,周生余,等.126例原发胃弥漫大B细胞淋巴瘤的临床特点及预后分析.中国肿瘤临床,2016,43(14):620-625.
[7]Qin Y, Liu P, Yang JL, et al. Clinical characteristics and treatment strategies for earlystage primary gastric diffuse large Bcell lymphoma. Zhonghua Yi Xue Za Zhi,2018,98(24):1945-1950.
[8]JuarezSalcedo LM, Sokol L, Chavez JC, et al. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control,2018, 25(1):1146213520.
[9]Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of earlystage H pyloripositive gastric diffuse large Bcell lymphomas. Blood,2012,119(21):4838-4844, 5057.
[10]Tanaka T, Shimada K, Yamamoto K, et al. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann Hematol,2012,91(3):383-390.
[11]孙俊杰,李双庆.多原发癌病因及发病机制的探索.中国全科医学,2017,20(9):1136-1141.
[12]熊媛媛,刘志娟,陈琳,等.淋巴瘤同时合并原发实体肿瘤17例临床分析.中华血液学杂志,2018,39(4):277-280.
[13]Hamaloglu E,Topaloglu S,Ozdemir A, et al. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: A review of the literature. World J Gastroenterol,2006,12(22):3564-3574.
[14]Peng C, Ouyang Y, Lu N, et al. The NFκB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: Recent advances. Front Immunol,2020,11:1387.
[15]Muzaheed. Helicobacter pylori oncogenicity: Mechanism, prevention, and risk factors. Sci World J,2020,2020:3018326.
[16]Zullo A, Licci S. Why does intestinal metaplasia develop early on gastric mucosa of mucosaassociated lymphoid tissue lymphoma patients? Ann Gastroenterol,2020,33(1):103.
[17]PimentelNunes P, Libanio D, MarcosPinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS Ⅱ): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy,2019,51(4):365-388.